Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report published on Thursday. The firm issued a strong-buy rating on the stock.

Several other equities analysts have also weighed in on the stock. Berenberg Bank started coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock. Truist Financial lifted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $22.48 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $13.19 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 1.03 and a beta of 0.91. The firm’s fifty day simple moving average is $20.93 and its 200 day simple moving average is $20.32. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $22.76.

Institutional Investors Weigh In On Fresenius Medical Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning increased its stake in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after buying an additional 6,373 shares during the period. Wulff Hansen & CO. increased its stake in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after buying an additional 325,439 shares during the period. Marshall Wace LLP increased its stake in Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after buying an additional 1,207 shares during the period. AQR Capital Management LLC bought a new stake in shares of Fresenius Medical Care in the 2nd quarter worth about $197,000. Finally, Moran Wealth Management LLC increased its position in shares of Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after purchasing an additional 74,621 shares during the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.